全文获取类型
收费全文 | 474篇 |
免费 | 34篇 |
国内免费 | 43篇 |
专业分类
551篇 |
出版年
2024年 | 3篇 |
2023年 | 2篇 |
2022年 | 25篇 |
2021年 | 29篇 |
2020年 | 16篇 |
2019年 | 20篇 |
2018年 | 21篇 |
2017年 | 22篇 |
2016年 | 16篇 |
2015年 | 22篇 |
2014年 | 32篇 |
2013年 | 33篇 |
2012年 | 44篇 |
2011年 | 38篇 |
2010年 | 19篇 |
2009年 | 28篇 |
2008年 | 30篇 |
2007年 | 26篇 |
2006年 | 19篇 |
2005年 | 10篇 |
2004年 | 10篇 |
2003年 | 9篇 |
2002年 | 7篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 4篇 |
1995年 | 15篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 1篇 |
排序方式: 共有551条查询结果,搜索用时 9 毫秒
31.
32.
Sun L Zhao H Xu Z Liu Q Liang Y Wang L Cai X Zhang L Hu L Wang G Zha X 《Cellular signalling》2007,19(11):2255-2263
DNA methylation, which affects gene expression and chromatin stability, is catalyzed by DNA methyltransferases (DNMTs) of which DNMT1 possesses most abundant activity. PI3K/PKB pathway is an important pathway involved in cell proliferation, viability, and metabolism and often disrupted in cancer. Here we investigated the impact of PKB on DNMT1 and DNA methylation. Positive correlation between PKB-Ser473-phosphorylation and DNMT1 protein level in 17 human cell lines (p<0.01) and in 27 human bladder cancer tissues (p<0.05) was found. With activator, inhibitor, siRNA and constitutively active or dominant-negative plasmids of PKB, we found that PKB increased the protein level of DNMT1 without coordinate mRNA change, which was specific rather than due to cell-cycle change. PKB enhanced DNMT1 protein stability independent of de novo synthesis of any protein, which was attributed to down-regulation of N-terminal-120-amino-acids-dependent DNMT1 degradation via ubiquitin-proteasome pathway. Gsk3beta inhibitor rescued the decrease of DNMT1 by PKB inhibition, suggesting that Gsk3beta mediated the stabilization of DNMT1 by PKB. Then role of PKB regulating DNMT1 was investigated. Inhibition of PKB caused observable DNA hypomethylation and chromatin decondensation and DNMT1 overexpression partially reversed cell growth inhibition by PKB inhibition. In conclusion, our results suggested that PKB enhanced DNMT1 stability and maintained DNA methylation and chromatin structure, which might contribute to cancer cell growth. 相似文献
33.
Peng H. Zhang G. H. Lu H. Q. Kong X. W. Zha X. D. Wang Y. Z. 《Applied Biochemistry and Microbiology》2022,58(5):627-634
Applied Biochemistry and Microbiology - Arthrobotrys oligospora is one of the most commonly studied fungi that can form abundant traps to capture and consume nematodes at the parasitic stage.... 相似文献
34.
Zhang Jianmin Zha Wenzhang Qian Changchun Ding Aixing Mao Zhongqi 《Biochemical genetics》2022,60(2):558-575
Biochemical Genetics - Resistance to cisplatin (CDDP) remains a major challenge for the treatment of gastric cancer (GC). Circular RNAs (circRNAs) have been implicated in the development of CDDP... 相似文献
35.
36.
Kais Z Barsky SH Mathsyaraja H Zha A Ransburgh DJ He G Pilarski RT Shapiro CL Huang K Parvin JD 《Molecular cancer research : MCR》2011,9(8):1091-1099
To find genes and proteins that collaborate with BRCA1 or BRCA2 in the pathogenesis of breast cancer, we used an informatics approach and found a candidate BRCA interactor, KIAA0101, to function like BRCA1 in exerting a powerful control over centrosome number. The effect of KIAA0101 on centrosomes is likely direct, as its depletion does not affect the cell cycle, KIAA0101 localizes to regions coincident with the centrosomes, and KIAA0101 binds to BRCA1. We analyzed whether KIAA0101 protein is overexpressed in breast cancer tumor samples in tissue microarrays, and we found that overexpression of KIAA0101 correlated with positive Ki67 staining, a biomarker associated with increased disease severity. Furthermore, overexpression of the KIAA0101 gene in breast tumors was found to be associated with significantly decreased survival time. This study identifies KIAA0101 as a protein important for breast tumorigenesis, and as this factor has been reported as a UV repair factor, it may link the UV damage response to centrosome control. 相似文献
37.
Ningyan Zhang Liming Liu Calin Dan Dumitru Nga Rewa Houston Cummings Michael Cukan Youwei Jiang Yuan Li Fang Li Teresa Mitchell Muralidhar R Mallem Yangsi Ou Rohan N Patel Kim Vo Hui Wang Irina Burnina Byung-Kwon Choi Hans Huber Terrance A Stadheim Dongxing Zha 《MABS-AUSTIN》2011,3(3):289-298
Mammalian cell culture systems are used predominantly for the production of therapeutic monoclonal antibody (mAb) products. A number of alternative platforms, such as Pichia engineered with a humanized N-linked glycosylation pathway, have recently been developed for the production of mAbs. The glycosylation profiles of mAbs produced in glycoengineered Pichia are similar to those of mAbs produced in mammalian systems. This report presents for the first time the comprehensive characterization of an anti-human epidermal growth factor receptor 2 (HER2) mAb produced in glycoengineered Pichia, and a study comparing the anti-HER2 from Pichia, which had an amino acid sequence identical to trastuzumab, with trastuzumab. The comparative study covered a full spectrum of preclinical evaluation, including bioanalytical characterization, in vitro biological functions, in vivo anti-tumor efficacy and pharmacokinetics in both mice and non-human primates. Cell signaling and proliferation assays showed that anti-HER2 from Pichia had antagonist activities comparable to trastuzumab. However, Pichia-produced material showed a 5-fold increase in binding affinity to FcγIIIA and significantly enhanced antibody dependent cell-mediated cytotoxicity (ADCC) activity, presumably due to the lack of fucose on N-glycans. In a breast cancer xenograft mouse model, anti-HER2 was comparable to trastuzumab in tumor growth inhibition. Furthermore, comparable pharmacokinetic profiles were observed for anti-HER2 and trastuzumab in both mice and cynomolgus monkeys. We conclude that glycoengineered Pichia provides an alternative production platform for therapeutic mAbs and may be of particular interest for production of antibodies for which ADCC is part of the clinical mechanism of action.Key words: glycoengineered Pichia, anti-HER2, trastuzumab, xenograft, PK, ADCC 相似文献
38.
39.